$6.02
0.091.60%
At Close: -
$6.00
-0.02-0.33%
After Hours: Jul 15, 6:45 PM EDT
15 minutes delayed
Comments
Loading...
Pasithea Therapeutics
KTTANASDAQ
Pasithea Therapeutics (NASDAQ:KTTA) Stock, Analyst Ratings, Price Targets, Forecasts
Pasithea Therapeutics Corp has a consensus price target of $2 based on the ratings of 2 analysts. The high is $2 issued by EF Hutton on July 10, 2023. The low is $2 issued by EF Hutton on July 10, 2023. The 3 most-recent analyst ratings were released by EF Hutton on July 10, 2023, June 1, 2023, and April 3, 2023, respectively. With an average price target of $2 between EF Hutton, there's an implied -66.78% downside for Pasithea Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
EF Hutton
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Pasithea Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2023 | Buy Now | -66.78% | EF Hutton | Elemer Piros | → $40 | Reiterates | Buy → Buy | Get Alert |
| 06/01/2023 | Buy Now | -66.78% | EF Hutton | Elemer Piros | → $40 | Assumes | → Buy | Get Alert |
| 04/03/2023 | Buy Now | -66.78% | EF Hutton | Constantine Davides | $46 → $40 | Maintains | Buy | Get Alert |
| 12/14/2021 | Buy Now | -46.01% | EF Hutton | Constantine Davides | → $65 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Pasithea Therapeutics (KTTA) stock?
The latest price target for Pasithea Therapeutics (NASDAQ:KTTA) was reported by EF Hutton on July 10, 2023. The analyst firm set a price target for $2.00 expecting KTTA to fall to within 12 months (a possible -66.67% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pasithea Therapeutics (KTTA)?
The latest analyst rating for Pasithea Therapeutics (NASDAQ:KTTA) was provided by EF Hutton, and Pasithea Therapeutics reiterated their buy rating.
When was the last upgrade for Pasithea Therapeutics (KTTA)?
There is no last upgrade for Pasithea Therapeutics
When was the last downgrade for Pasithea Therapeutics (KTTA)?
There is no last downgrade for Pasithea Therapeutics.
When is the next analyst rating going to be posted or updated for Pasithea Therapeutics (KTTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pasithea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pasithea Therapeutics was filed on July 10, 2023 so you should expect the next rating to be made available sometime around July 10, 2024.
Is the Analyst Rating Pasithea Therapeutics (KTTA) correct?
While ratings are subjective and will change, the latest Pasithea Therapeutics (KTTA) rating was a reiterated with a price target of $0.00 to $2.00. The current price Pasithea Therapeutics (KTTA) is trading at is $6.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.